CD8A and neoplasm: found that compared with low-dose daily fractionated IR (2 Gy×10), high-dose hypofractioned IR (8 Gy×2) preserves or enhances anti-tumor immunity to control primary and distant tumors through accumulating and activating peripheral and tumor-infiltrating CD8+T-lymphocyte and reducing peripheral and tumor gMDSC accumulation (64).